CareDx CDNA Testing services revenue — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by CareDx in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: CareDx’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about CareDx's testing services revenue — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CareDx's testing services revenue — total revenue?
- CareDx (CDNA) reported testing services revenue — total revenue of $91.4M in Q1 2026.
- How has CareDx's testing services revenue — total revenue changed year-over-year?
- CareDx's testing services revenue — total revenue increased by 47.6% year-over-year, from $61.92M to $91.4M.
- What is the long-term trend for CareDx's testing services revenue — total revenue?
- Over 4 years (2021 to 2025), CareDx's testing services revenue — total revenue has grown at a 1.4% compound annual growth rate (CAGR), from $259.29M to $274.5M.
- What does testing services revenue — total revenue mean?
- This metric represents the total gross revenue generated from the company's specialized testing services, products, and digital solutions provided to transplant patients and caregivers. It serves as a primary indicator of market adoption and commercial scale for the company's core genomics-based diagnostic offerings. Tracking this figure helps investors assess the growth trajectory and revenue-generating capacity of the firm's transplant-focused business segment.